DOCSLIB.ORG

US 2020/0078401 A1 VIJAYANAND Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US 20200078401A1 IN ( 19 ) United States (12 ) Patent Application Publication ( 10) Pub . No .: US 2020/0078401 A1 VIJAYANAND et al. (43 ) Pub . Date : Mar. 12 , 2020 (54 ) COMPOSITIONS FOR CANCER (52 ) U.S. CI. TREATMENT AND METHODS AND USES CPC A61K 35/17 ( 2013.01) ; A61K 45/06 FOR CANCER TREATMENT AND ( 2013.01 ) ; C120 1/6886 ( 2013.01 ) ; A61P PROGNOSIS 35/00 (2018.01 ) ( 71 ) Applicants : La Jolla Institute for Allergy and Immunology , La Jolla , CA (US ) ; UNIVERSITY OF SOUTHAMPTON , (57 ) ABSTRACT Hampshire (GB ) (72 ) Inventors : Pandurangan VIJAYANAND , La Jolla , CA (US ) ; Christian Global transcriptional profiling of CTLs in tumors and OTTENSMEIER , Hampshire (GB ) ; adjacent non -tumor tissue from treatment- naive patients Anusha PreethiGANESAN , La Jolla , with early stage lung cancer revealed molecular features CA (US ) ; James CLARKE , Hampshire associated with robustness of anti - tumor immune responses . (GB ) ; Tilman SANCHEZ - ELSNER , Major differences in the transcriptional program of tumor Hampshire (GB ) infiltrating CTLswere observed that are shared across tumor subtypes . Pathway analysis revealed enrichment of genes in ( 21 ) Appl. No .: 16 / 465,983 cell cycle , T cell receptor ( TCR ) activation and co -stimula tion pathways , indicating tumor- driven expansion of pre ( 22 ) PCT Filed : Dec. 7 , 2017 sumed tumor antigen - specific CTLs. Marked heterogeneity in the expression ofmolecules associated with TCR activa ( 86 ) PCT No .: PCT /US2017 / 065197 tion and immune checkpoints such as 4-1BB , PD1, TIM3, $ 371 ( c ) ( 1 ) , was also observed and their expression was positively ( 2 ) Date : May 31 , 2019 correlated with the density of tumor- infiltrating CTLs. Tran scripts linked to tissue- resident memory cells ( TRM ), such Related U.S. Application Data as CD 103 , were enriched in tumors containing a high (60 ) Provisional application No.62 / 431,265 , filed on Dec. density of CTLs, and CTLS from CD 103 high tumors dis 7 , 2016 , provisional application No. 62 /522,048 , filed played features of enhanced cytotoxicity , implying better anti- tumor activity . In an independent cohort of 689 lung on Jun . 19 , 2017 . cancer patients , patients with CD103 high (TRM rich ) tumors Publication Classification survived significantly longer. In summary , the molecular ( 51 ) Int . Cl. fingerprint of tumor- infiltrating CTLs at the site of primary A61K 35/17 ( 2006.01 ) tumor was defined and a number of novel targets identified A61P 35/00 ( 2006.01) that appear to be important in modulating the magnitude and C12Q 1/6886 ( 2006.01 ) specificity of anti -tumor immune responses in lung cancer . Exhaustion signature (up genes ) Exhaustion signature ( down genes ) Lung cancer T cell signature (up genes ) Anergy signature (up genes ) Senescence signature (up genes ) 0 4 P0.04 0.2 P = 0.02 P = 0.02 0.4 P0.38 P = 018 q = 0.11 0.5 0.2 0 = 0.11 q = 0.03 q = 0 : 23 RES 0 . RES -0.2 RES -0.4 -0.4 1 10 10 Metric Metric Metric Metric 10 Metric -10 5 5 20 " 10 5 20 Variable index (x1000 ) Patent Application Publication Mar. 12 , 2020 Sheet 1 of 17 US 2020/0078401 A1 P0.18 0.23q= 20 Senescencesignature(upgenes) 15 10 6 0.4 RES -0.4Ò Metric -10 20 P-0.38 0.38=q 15 10 5 0.4 RES -0.4 Metric-10 20" P=0.02 0.03=q Exhaustionsignature(downgenes)LungcancerTcellsignatureupgenesAnergysignature(genes) 15' 10' Fig.1 5 0.5 RES -0.5 Metric-10 P.0.02 0.11=q ------------ 20" 15" 10' 5 ha 0.2 -0.2 0.4 10 RES Metric P=0.04 0.11=Q Exhaustionsignature(upgenes) 10*15520 Variableindex(x1000) 10 0.4 0.2 .-10 -0.2 Metric Patent Application Publication Mar. 12 , 2020 Sheet 2 of 17 US 2020/0078401 A1 -Log (Pvalue ) 2.5 7.5 5.0 -Log(Pvalue) 52 Upregulated Downregulated 70 47 lymphocytesinsignaling CD27 187 signalingINOS 87 junctionneuromuscular atinteractions Agrin 14 activationvirusesincell activation stellate NFB& fibrosis Hepatic 25225315 synthesisnovo de ATMP 40 RAsignalingincells cytokineendothelial IL6 in&kinases fibroblasts JAK ,Macrophages 247 38 signalingfactormetastasis activating cancer cellColorectal B 55 72 compoundssignalingmediated phosphate APRIL inositol ot pathway Super controlcycle cell in proteins CHK of Role 154117197 Signalingdifferentiationp53 Thelper 2A.Fig 27402 metabolismphosphate myoinositol -D signalingsynthesisAphosphoinositidekinase Protein -3 135 153 replication)chromosoma ofcontrol cycle Cell synthesistetrakisphosphate )3,4,5,8 (myoinositol -D 88 synthesisdegradationtetrakisphosphate phosphoinositide )1,4,5,8-3 (myoinositol -D 66 lymphocytesinsignaling 4-1BB RAinsignaling cell B& T Altered 78 KinaseLike -Polo of roles Mitotic 144238 HBCSregulationresponse checkpointdamage DNA damage inBRCA1 DNA of MRole/G2 : cycle Cell 59 RAinosteoclast ,Osteoblast 100 signalingATM Percent Patent Application Publication Mar. 12 , 2020 Sheet 3 of 17 US 2020/0078401 A1 JUNJUN 2kb Chr1 20.5 20.51 14 12 Polo-LikeKinase(9) ATMsignaling(13) 49.6kb Mitoticrolesof 4 P53signaling(9) Chr12 81 INFRSF9CD2 10.8, 10.8 12 10 ... www 7,3kb regulation(8) Chr114-1BB) cycle:G2/MDNACell damagecheckpoint FIG.2B 4.6 12 9 FIG.2C 68kb response10)( CCNB1 Chr5 0.6 3 RoleofBRCA1in 0.6 control(6) cancersignaling(14) DNAdamage RoleofCHKproteinsIncellcyclecheckpoint 4 Hereditarybreast PLK1 wwwwwwwww 7.3kb Chr16 0.4 0.47 ) RPKM ( ) normalized( Expression RNA Expression Patent Application Publication Mar. 12 , 2020 Sheet 4 of 17 US 2020/0078401 A1 NSOLOTIL Ligand Transmembrane receptor Transporter EnzymeTranscriptiora Mregulator Kinase Complex Upregulated TRAF5 Y V00271 CD27 ATRAF2 MEKK 45.3 SNIK InducedCell Death TRAF2 OIKK NFB TILLungN- psa FIG.2E 4-1BBL 4-1BB JASK1 MAPK INK Cytotoxicity FIG.2D TRAFI MEK1/2 oo ERKTA2UNK ASIAN extracellular space Cytoplasm CORNER Nucleus Proliferation PBMC 010 .. Patent Application Publication Mar. 12 , 2020 Sheet 5 of 17 US 2020/0078401 A1 left()UNTIL TILONcenter() Tilhigh(right) N-TL TILDW TILNgh TIGIT 7.3kb Chr3 11,7 11,7 117 13 12 11 10 LungTIL.N- NSCLCTIL 2.6kb LAG3Chr12 REG 901 9.1 9.1 13 12 11 (TIM3)HAVCR2 10.2kb Fig.3 2FFig. Chr5 5 Frequentclonotypes ???????? 11.7kb (4-1BB) ?????????????? TNFASFOOhi 62 62 62 12 10 8 clonotypes of Number PDCD1 3.9kb Chr2 ) RPKM( ) normalized( Expression RNA Expression Patent Application Publication Mar. 12 , 2020 Sheet 6 of 17 US 2020/0078401 A1 highTIL N-TIL TLbW STK38 23.5kb Chr6 8 2.2 2.2 2.2 11 10 KLF2 1.1kb honde 9 Chr19 17,3 13 TILhigh(right) S1PA1 2.0kb Chr1 4AFig. 13.7 13.7 14 10 N-TILleft()ATILIWcenter) CXOR 2.1Kb Chr3 4 23.7 23.7 23.7 13 12 10 ITCAE onhimpunan ..... 37.2kb Chr17 8 6.6 6.6 12 ) RPKM( )normalized ( Expression ANA Expression Patent Application Publication Mar. 12 , 2020 Sheet 7 of 17 US 2020/0078401 A1 31.5 26:3 28 OD103 NSCLCTIL 49.6 1.6 65.8 1.5 66 43.5 5.9 PD1 LungTILN- FIG.4B 1.3 918 1.2 FIG.40 0.7 44.8 0.05 0:1 CD8a PBM 54.2 1.35 97.2 CD103 0.8 97.7 CD103 CD103 CD8 PD1 4-1BB TILlowNSCLC NSCLChighTIL Patent Application Publication Mar. 12 , 2020 Sheet 8 of 17 US 2020/0078401 A1 SA 31.3 P<0.001 0.005=q 1520 Variableindex(x1000) CD49a TRM(downgenes) 5 CD69 COR7 31.7 0 0.2 -0.2 10 RES Metric SEN FIG.4D FIG.4E 1612 CD49a 12900 0.56P= 0.55q= 31.1 2.2 286 TAM(upgenes) 1551020 Variableindex(x1000) 28.6 CD103 CD69 KLRG1 CD103 nown 0.4 0.2 0.2 -0.4 -10 RES Metric Patent Application Publication Mar. 12 , 2020 Sheet 9 of 17 US 2020/0078401 A1 CD103low(center) CD103high(right) N-TIL(left) TILN- CD10310 CD103high Upregulated(all) 4.8kb Chir17BIRC5 BROW 73.7 Cytokine Enzyme TranscriptionalRegulator Phosphatase Peptidase Other 1.1 1.1 1.1 10 NSOLCIIL kb8.5 GBP4 GBP5 OUT 0.2 421.4 GBP2 Chr15CCNB2 GBP1 COWOTCH1 80453* 1.1 10 0.2 2016 ... PARPO TILhungN- SCD38 HOW 7.5kb FIG.5A FIG.5B CCL5 FIG.4F AURKBChr17 10.7 78.5 BCDIPSMB 0.9 09 COLBY their Internet 1.8kb BST20 PSMBS CDC20 ........ PBMC UBE2L62 PSMEZ? Chr1 1.2 1.2 10 12.2 192.6 STATZCO STATU SEC11A RARRES K167 CD103 18.5kb 18 ACC Chr14.DLGAPS 0.8 0.8 ) RPKM( ) normalized( Expression Expression Patent Application Publication Mar. 12 , 2020 Sheet 10 of 17 US 2020/0078401 A1 P0.036= CDShightumors CD103high 200030004000 LCD1036 Days FIG.5G CD103low(center) CD103high(right) 1000 IN-TIL(left) 80 40 20 0 332 100 30.7 46.3 206 survival Percent IFNG SC 14 A Granzyme P=0.043 4000 ) normalized( .IFNY Expression IFNG 396 224 20.4 CD103high CD103low 3000 2000 Days FIG.5F GZMA FIG.5D FIG.5C 13.9 22.6 9.8 S 1000 B Granzyme 103CD ) nomalized( Expression GZMA 100 80. 60 40 20 CD103low CD103high survival Percent CD8*TILS GZMB 33.8 Perforin CD103 P=0.086 4000 ) nomalized( GZMB of MFI Expression GZMB highCD CD8low 3000 2000 Days FIG.5E 1000 100 80 60 40 20 survival Percent Patent Application Publication Mar. 12 , 2020 Sheet 11 of 17 US 2020/0078401 A1 CD103center() high(right)CD103 N-TIL(left) CD8+CD103TILS-left() CDB+CD103*Tiloright() RBPJ 15 - URC TUUT + CD39 of % 12 . NABI P2RX7 100 + CD38 of % 12 6 N BATF SIRPG FIG.6A 29.01 FIG.6B 8 CD39 29,9 10,5 7.5. KIR2DL4 CD39 2 CD38 ) namalized( expression 5.5. 0.5. CD38 ) Expressionnormalized( 59.8 35.2 KIA2DL4 CD103 Patent Application Publication Mar. 12 , 2020 Sheet 12 of 17 US 2020/0078401 A1 S100A10 6X3071 w S1PRI Reducedcellmovement G-proteincoupledreceptor Peptidase Downregulated Cytokine Other FIG.7A CAST TIMP7 0 TNF Patent Application Publication Mar.
Recommended publications
  • Inhibition of Breast and Brain Cancer Cell Growth by Bccipα, An

    Inhibition of Breast and Brain Cancer Cell Growth by Bccipα, An

    Oncogene (2001) 20, 336 ± 345 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc Inhibition of breast and brain cancer cell growth by BCCIPa,an evolutionarily conserved nuclear protein that interacts with BRCA2 Jingmei Liu1, Yuan Yuan1,2, Juan Huan2 and Zhiyuan Shen*,1 1Department of Molecular Genetics and Microbiology, University of New Mexico Health Sciences Center; 915 Camino de Salud, NE. Albuquerque, New Mexico, NM 87131, USA; 2Graduate Program of Molecular Genetics, College of Medicine, University of Illinois at Chicago, 900 S. Ashland Ave. Chicago, Illinois, IL 60607, USA BRCA2 is a tumor suppressor gene involved in mammary mouse BRCA2. It is expected that important functions tumorigenesis. Although important functions have been of BRCA2 reside in these conserved domains. Based on assigned to a few conserved domains of BRCA2, little is the functional analysis of the conserved BRCA2 known about the longest internal conserved domain domains, several models have been proposed for the encoded by exons 14 ± 24. We identi®ed a novel protein, role of BRCA2 in tumor suppression. designated BCCIPa, that interacts with part of the An N-terminus conserved domain in exon 3 (amino internal conserved region of human BRCA2. Human acids 48 ± 105) has been implicated in transcriptional BCCIP represents a family of proteins that are regulation of gene expression (Milner et al., 1997; evolutionarily conserved, and contain three distinct Nordling et al., 1998). Deletion of this region has been domains: an N-terminus acidic domain (NAD) of 30 ± identi®ed in breast cancers (Nordling et al., 1998).
  • Analysis of Trans Esnps Infers Regulatory Network Architecture

    Analysis of Trans Esnps Infers Regulatory Network Architecture

    Analysis of trans eSNPs infers regulatory network architecture Anat Kreimer Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2014 © 2014 Anat Kreimer All rights reserved ABSTRACT Analysis of trans eSNPs infers regulatory network architecture Anat Kreimer eSNPs are genetic variants associated with transcript expression levels. The characteristics of such variants highlight their importance and present a unique opportunity for studying gene regulation. eSNPs affect most genes and their cell type specificity can shed light on different processes that are activated in each cell. They can identify functional variants by connecting SNPs that are implicated in disease to a molecular mechanism. Examining eSNPs that are associated with distal genes can provide insights regarding the inference of regulatory networks but also presents challenges due to the high statistical burden of multiple testing. Such association studies allow: simultaneous investigation of many gene expression phenotypes without assuming any prior knowledge and identification of unknown regulators of gene expression while uncovering directionality. This thesis will focus on such distal eSNPs to map regulatory interactions between different loci and expose the architecture of the regulatory network defined by such interactions. We develop novel computational approaches and apply them to genetics-genomics data in human. We go beyond pairwise interactions to define network motifs, including regulatory modules and bi-fan structures, showing them to be prevalent in real data and exposing distinct attributes of such arrangements. We project eSNP associations onto a protein-protein interaction network to expose topological properties of eSNPs and their targets and highlight different modes of distal regulation.
  • Acidic Phospholipids,47, 58 Acidification Steps, 23 Adsorbent, 53

    Acidic Phospholipids,47, 58 Acidification Steps, 23 Adsorbent, 53

    Index acidic phospholipids,47, 58 ATPase, 22, 107 acidification steps, 23 auto-oxidation, 48,49 adsorbent, 53 aequorin, 95 aggregated mitochondria, 23 bacterial cells, 10 alcohols, 49 bacteriorhodopsin (BR), 218,232 alkaline hydrolysis, I bee venom, 121 alkyl esters, 57, 59 binders,53 amide bond, 129 silica gel, 53, 65, 176 amide linkage, 14 silica gel H, 176 amino alcohol, II bioactive phospholipids, 144 amino-group labelling reagents, 121 blanching, 50 aminopeptidase, 17 buoyant density, 16 aminophospholipid, 113, 118 butyl hydroxy toluene (BHT), 49,212 aminophospholipid pump, 119, 140 aminophospholipid translocase, 11 3 amphotericin B (AmB), 107 Cal+ -ATPases, 28, 107 N-(1-deoxyD-fructos-1-yl) AmB, 107 Cal+ -uptake, 27 anchored lipids, 38 campesterol, 104 angular amplitude, 89 calciferol, 78 anilino-8-naphthalene sulfonate (ANS), Candida albicans, 59, 60, 61, 76, 78, 102, 94, 103 104, 108 animal cells, 10 caproic acid, 129, 130 animal tissues, 9 carotenoids, 37 anion transporter, 135 cell debris, 33 anisotropy, 81 , 89, 95, 96, 97, 102, 104, cell disintegrator, 19 105 ceramide, 14, 129, 194 antagonists, 178 ceramide monohexosides ( CMH), 60 antioxidant, 49, 50 cerebroside, 14 apolar lipids, 56, 57, 69 chemical probes,112 arachidonic acid (AA), 144,153, 161 chloroplast, 32, 33 artificial membrane, 83 isolation, 32, 33 ascending chromatography, 54 purification, 33 asymmetric topology, 128 cholesterol, 14, 15,212 asymmetry, 112, 113,119 choline, 7, 9 atebrin, 95 chromatograms, 55 Index 249 chromatographic analyses, 52 ELISA, 146, 148
  • SPATA33 Localizes Calcineurin to the Mitochondria and Regulates Sperm Motility in Mice

    SPATA33 Localizes Calcineurin to the Mitochondria and Regulates Sperm Motility in Mice

    SPATA33 localizes calcineurin to the mitochondria and regulates sperm motility in mice Haruhiko Miyataa, Seiya Ouraa,b, Akane Morohoshia,c, Keisuke Shimadaa, Daisuke Mashikoa,1, Yuki Oyamaa,b, Yuki Kanedaa,b, Takafumi Matsumuraa,2, Ferheen Abbasia,3, and Masahito Ikawaa,b,c,d,4 aResearch Institute for Microbial Diseases, Osaka University, Osaka 5650871, Japan; bGraduate School of Pharmaceutical Sciences, Osaka University, Osaka 5650871, Japan; cGraduate School of Medicine, Osaka University, Osaka 5650871, Japan; and dThe Institute of Medical Science, The University of Tokyo, Tokyo 1088639, Japan Edited by Mariana F. Wolfner, Cornell University, Ithaca, NY, and approved July 27, 2021 (received for review April 8, 2021) Calcineurin is a calcium-dependent phosphatase that plays roles in calcineurin can be a target for reversible and rapidly acting male a variety of biological processes including immune responses. In sper- contraceptives (5). However, it is challenging to develop molecules matozoa, there is a testis-enriched calcineurin composed of PPP3CC and that specifically inhibit sperm calcineurin and not somatic calci- PPP3R2 (sperm calcineurin) that is essential for sperm motility and male neurin because of sequence similarities (82% amino acid identity fertility. Because sperm calcineurin has been proposed as a target for between human PPP3CA and PPP3CC and 85% amino acid reversible male contraceptives, identifying proteins that interact with identity between human PPP3R1 and PPP3R2). Therefore, identi- sperm calcineurin widens the choice for developing specific inhibitors. fying proteins that interact with sperm calcineurin widens the choice Here, by screening the calcineurin-interacting PxIxIT consensus motif of inhibitors that target the sperm calcineurin pathway. in silico and analyzing the function of candidate proteins through the The PxIxIT motif is a conserved sequence found in generation of gene-modified mice, we discovered that SPATA33 inter- calcineurin-binding proteins (8, 9).
  • Identification and Characterization of TPRKB Dependency in TP53 Deficient Cancers

    Identification and Characterization of TPRKB Dependency in TP53 Deficient Cancers

    Identification and Characterization of TPRKB Dependency in TP53 Deficient Cancers. by Kelly Kennaley A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Molecular and Cellular Pathology) in the University of Michigan 2019 Doctoral Committee: Associate Professor Zaneta Nikolovska-Coleska, Co-Chair Adjunct Associate Professor Scott A. Tomlins, Co-Chair Associate Professor Eric R. Fearon Associate Professor Alexey I. Nesvizhskii Kelly R. Kennaley [email protected] ORCID iD: 0000-0003-2439-9020 © Kelly R. Kennaley 2019 Acknowledgements I have immeasurable gratitude for the unwavering support and guidance I received throughout my dissertation. First and foremost, I would like to thank my thesis advisor and mentor Dr. Scott Tomlins for entrusting me with a challenging, interesting, and impactful project. He taught me how to drive a project forward through set-backs, ask the important questions, and always consider the impact of my work. I’m truly appreciative for his commitment to ensuring that I would get the most from my graduate education. I am also grateful to the many members of the Tomlins lab that made it the supportive, collaborative, and educational environment that it was. I would like to give special thanks to those I’ve worked closely with on this project, particularly Dr. Moloy Goswami for his mentorship, Lei Lucy Wang, Dr. Sumin Han, and undergraduate students Bhavneet Singh, Travis Weiss, and Myles Barlow. I am also grateful for the support of my thesis committee, Dr. Eric Fearon, Dr. Alexey Nesvizhskii, and my co-mentor Dr. Zaneta Nikolovska-Coleska, who have offered guidance and critical evaluation since project inception.
  • Bioluminescent Properties of Semi-Synthetic Obelin and Aequorin Activated by Coelenterazine Analogues with Modifications of C-2, C-6, and C-8 Substituents

    Bioluminescent Properties of Semi-Synthetic Obelin and Aequorin Activated by Coelenterazine Analogues with Modifications of C-2, C-6, and C-8 Substituents

    International Journal of Molecular Sciences Article Bioluminescent Properties of Semi-Synthetic Obelin and Aequorin Activated by Coelenterazine Analogues with Modifications of C-2, C-6, and C-8 Substituents 1, 2,3, 1 2, Elena V. Eremeeva y , Tianyu Jiang y , Natalia P. Malikova , Minyong Li * and Eugene S. Vysotski 1,* 1 Photobiology Laboratory, Institute of Biophysics SB RAS, Federal Research Center “Krasnoyarsk Science Center SB RAS”, Krasnoyarsk 660036, Russia; [email protected] (E.V.E.); [email protected] (N.P.M.) 2 Key Laboratory of Chemical Biology (MOE), Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China; [email protected] 3 State Key Laboratory of Microbial Technology, Shandong University–Helmholtz Institute of Biotechnology, Shandong University, Qingdao 266237, China * Correspondence: [email protected] (M.L.); [email protected] (E.S.V.); Tel.: +86-531-8838-2076 (M.L.); +7-(391)-249-44-30 (E.S.V.); Fax: +86-531-8838-2076 (M.L.); +7-(391)-290-54-90 (E.S.V.) These authors contributed equally to this work. y Received: 23 June 2020; Accepted: 27 July 2020; Published: 30 July 2020 Abstract: Ca2+-regulated photoproteins responsible for bioluminescence of a variety of marine organisms are single-chain globular proteins within the inner cavity of which the oxygenated coelenterazine, 2-hydroperoxycoelenterazine, is tightly bound. Alongside with native coelenterazine, photoproteins can also use its synthetic analogues as substrates to produce flash-type bioluminescence. However, information on the effect of modifications of various groups of coelenterazine and amino acid environment of the protein active site on the bioluminescent properties of the corresponding semi-synthetic photoproteins is fragmentary and often controversial.
  • Bioinformatics Analyses of Genomic Imprinting

    Bioinformatics Analyses of Genomic Imprinting

    Bioinformatics Analyses of Genomic Imprinting Dissertation zur Erlangung des Grades des Doktors der Naturwissenschaften der Naturwissenschaftlich-Technischen Fakultät III Chemie, Pharmazie, Bio- und Werkstoffwissenschaften der Universität des Saarlandes von Barbara Hutter Saarbrücken 2009 Tag des Kolloquiums: 08.12.2009 Dekan: Prof. Dr.-Ing. Stefan Diebels Berichterstatter: Prof. Dr. Volkhard Helms Priv.-Doz. Dr. Martina Paulsen Vorsitz: Prof. Dr. Jörn Walter Akad. Mitarbeiter: Dr. Tihamér Geyer Table of contents Summary________________________________________________________________ I Zusammenfassung ________________________________________________________ I Acknowledgements _______________________________________________________II Abbreviations ___________________________________________________________ III Chapter 1 – Introduction __________________________________________________ 1 1.1 Important terms and concepts related to genomic imprinting __________________________ 2 1.2 CpG islands as regulatory elements ______________________________________________ 3 1.3 Differentially methylated regions and imprinting clusters_____________________________ 6 1.4 Reading the imprint __________________________________________________________ 8 1.5 Chromatin marks at imprinted regions___________________________________________ 10 1.6 Roles of repetitive elements ___________________________________________________ 12 1.7 Functional implications of imprinted genes _______________________________________ 14 1.8 Evolution and parental conflict ________________________________________________
  • IL21R Expressing CD14+CD16+ Monocytes Expand in Multiple

    IL21R Expressing CD14+CD16+ Monocytes Expand in Multiple

    Plasma Cell Disorders SUPPLEMENTARY APPENDIX IL21R expressing CD14 +CD16 + monocytes expand in multiple myeloma patients leading to increased osteoclasts Marina Bolzoni, 1 Domenica Ronchetti, 2,3 Paola Storti, 1,4 Gaetano Donofrio, 5 Valentina Marchica, 1,4 Federica Costa, 1 Luca Agnelli, 2,3 Denise Toscani, 1 Rosanna Vescovini, 1 Katia Todoerti, 6 Sabrina Bonomini, 7 Gabriella Sammarelli, 1,7 Andrea Vecchi, 8 Daniela Guasco, 1 Fabrizio Accardi, 1,7 Benedetta Dalla Palma, 1,7 Barbara Gamberi, 9 Carlo Ferrari, 8 Antonino Neri, 2,3 Franco Aversa 1,4,7 and Nicola Giuliani 1,4,7 1Myeloma Unit, Dept. of Medicine and Surgery, University of Parma; 2Dept. of Oncology and Hemato-Oncology, University of Milan; 3Hematology Unit, “Fondazione IRCCS Ca’ Granda”, Ospedale Maggiore Policlinico, Milan; 4CoreLab, University Hospital of Parma; 5Dept. of Medical-Veterinary Science, University of Parma; 6Laboratory of Pre-clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture; 7Hematology and BMT Center, University Hospital of Parma; 8Infectious Disease Unit, University Hospital of Parma and 9“Dip. Oncologico e Tecnologie Avanzate”, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy ©2017 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2016.153841 Received: August 5, 2016. Accepted: December 23, 2016. Pre-published: January 5, 2017. Correspondence: [email protected] SUPPLEMENTAL METHODS Immunophenotype of BM CD14+ in patients with monoclonal gammopathies. Briefly, 100 μl of total BM aspirate was incubated in the dark with anti-human HLA-DR-PE (clone L243; BD), anti-human CD14-PerCP-Cy 5.5, anti-human CD16-PE-Cy7 (clone B73.1; BD) and anti-human CD45-APC-H 7 (clone 2D1; BD) for 20 min.
  • Macropinocytosis Requires Gal-3 in a Subset of Patient-Derived Glioblastoma Stem Cells

    Macropinocytosis Requires Gal-3 in a Subset of Patient-Derived Glioblastoma Stem Cells

    ARTICLE https://doi.org/10.1038/s42003-021-02258-z OPEN Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells Laetitia Seguin1,8, Soline Odouard2,8, Francesca Corlazzoli 2,8, Sarah Al Haddad2, Laurine Moindrot2, Marta Calvo Tardón3, Mayra Yebra4, Alexey Koval5, Eliana Marinari2, Viviane Bes3, Alexandre Guérin 6, Mathilde Allard2, Sten Ilmjärv6, Vladimir L. Katanaev 5, Paul R. Walker3, Karl-Heinz Krause6, Valérie Dutoit2, ✉ Jann N. Sarkaria 7, Pierre-Yves Dietrich2 & Érika Cosset 2 Recently, we involved the carbohydrate-binding protein Galectin-3 (Gal-3) as a druggable target for KRAS-mutant-addicted lung and pancreatic cancers. Here, using glioblastoma patient-derived stem cells (GSCs), we identify and characterize a subset of Gal-3high glio- 1234567890():,; blastoma (GBM) tumors mainly within the mesenchymal subtype that are addicted to Gal-3- mediated macropinocytosis. Using both genetic and pharmacologic inhibition of Gal-3, we showed a significant decrease of GSC macropinocytosis activity, cell survival and invasion, in vitro and in vivo. Mechanistically, we demonstrate that Gal-3 binds to RAB10, a member of the RAS superfamily of small GTPases, and β1 integrin, which are both required for macro- pinocytosis activity and cell survival. Finally, by defining a Gal-3/macropinocytosis molecular signature, we could predict sensitivity to this dependency pathway and provide proof-of- principle for innovative therapeutic strategies to exploit this Achilles’ heel for a significant and unique subset of GBM patients. 1 University Côte d’Azur, CNRS UMR7284, INSERM U1081, Institute for Research on Cancer and Aging (IRCAN), Nice, France. 2 Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
  • A. Cellular Senescence

    A. Cellular Senescence

    Generation of antisense RNAs at convergent gene loci in cells undergoing senescence Maharshi Krishna Deb To cite this version: Maharshi Krishna Deb. Generation of antisense RNAs at convergent gene loci in cells undergo- ing senescence. Human genetics. Université Paul Sabatier - Toulouse III, 2016. English. NNT : 2016TOU30274. tel-03209213 HAL Id: tel-03209213 https://tel.archives-ouvertes.fr/tel-03209213 Submitted on 27 Apr 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. 5)µ4& &OWVFEFMPCUFOUJPOEV %0$503"5%&-6/*7&34*5²%&506-064& %ÏMJWSÏQBS Université Toulouse 3 Paul Sabatier (UT3 Paul Sabatier) 1SÏTFOUÏFFUTPVUFOVFQBS DEB Maharshi Krishna -F mercredi 30 mars 2016 5Jtre : Generation of antisense RNAs at convergent gene loci in cells undergoing senescence École doctorale et discipline ou spécialité : ED BSB : Génétique moléculaire 6OJUÏEFSFDIFSDIF CNRS-UMR5088; LBCMCP %JSFDUFVS T EFʾÒTF Dr. TROUCHE Didier Co-Directeur/trice(s) de Thèse : Dr. NICOLAS Estelle 3BQQPSUFVST Prof. GILSON Eric, Dr. LIBRI Domenico, Dr. VERDEL Andre "VUSF T NFNCSF T EVKVSZ Prof. GLEIZES Pierre Emmanuel, President of Jury Dr. TROUCHE Didier, Thesis Supervisor This thesis is dedicated to any patients who may get cured with treatments manifesting from this work.
  • Noelia Díaz Blanco

    Noelia Díaz Blanco

    Effects of environmental factors on the gonadal transcriptome of European sea bass (Dicentrarchus labrax), juvenile growth and sex ratios Noelia Díaz Blanco Ph.D. thesis 2014 Submitted in partial fulfillment of the requirements for the Ph.D. degree from the Universitat Pompeu Fabra (UPF). This work has been carried out at the Group of Biology of Reproduction (GBR), at the Department of Renewable Marine Resources of the Institute of Marine Sciences (ICM-CSIC). Thesis supervisor: Dr. Francesc Piferrer Professor d’Investigació Institut de Ciències del Mar (ICM-CSIC) i ii A mis padres A Xavi iii iv Acknowledgements This thesis has been made possible by the support of many people who in one way or another, many times unknowingly, gave me the strength to overcome this "long and winding road". First of all, I would like to thank my supervisor, Dr. Francesc Piferrer, for his patience, guidance and wise advice throughout all this Ph.D. experience. But above all, for the trust he placed on me almost seven years ago when he offered me the opportunity to be part of his team. Thanks also for teaching me how to question always everything, for sharing with me your enthusiasm for science and for giving me the opportunity of learning from you by participating in many projects, collaborations and scientific meetings. I am also thankful to my colleagues (former and present Group of Biology of Reproduction members) for your support and encouragement throughout this journey. To the “exGBRs”, thanks for helping me with my first steps into this world. Working as an undergrad with you Dr.
  • Role of Amylase in Ovarian Cancer Mai Mohamed University of South Florida, Mmohamed@Health.Usf.Edu

    Role of Amylase in Ovarian Cancer Mai Mohamed University of South Florida, [email protected]

    University of South Florida Scholar Commons Graduate Theses and Dissertations Graduate School July 2017 Role of Amylase in Ovarian Cancer Mai Mohamed University of South Florida, [email protected] Follow this and additional works at: http://scholarcommons.usf.edu/etd Part of the Pathology Commons Scholar Commons Citation Mohamed, Mai, "Role of Amylase in Ovarian Cancer" (2017). Graduate Theses and Dissertations. http://scholarcommons.usf.edu/etd/6907 This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact [email protected]. Role of Amylase in Ovarian Cancer by Mai Mohamed A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Pathology and Cell Biology Morsani College of Medicine University of South Florida Major Professor: Patricia Kruk, Ph.D. Paula C. Bickford, Ph.D. Meera Nanjundan, Ph.D. Marzenna Wiranowska, Ph.D. Lauri Wright, Ph.D. Date of Approval: June 29, 2017 Keywords: ovarian cancer, amylase, computational analyses, glycocalyx, cellular invasion Copyright © 2017, Mai Mohamed Dedication This dissertation is dedicated to my parents, Ahmed and Fatma, who have always stressed the importance of education, and, throughout my education, have been my strongest source of encouragement and support. They always believed in me and I am eternally grateful to them. I would also like to thank my brothers, Mohamed and Hussien, and my sister, Mariam. I would also like to thank my husband, Ahmed.